Dr. Weisman sat down with NBC10’s Keith Jones to discuss the effects of Alzheimer’s disease and the NOBLE clinical trial.
Dr. Weisman was recognized as an investigator in the Alzheimer’s Disease Cooperative Study.
ANA is one of the few centers in the region offering experimental treatment options for Alzheimer’s disease.
Dr. Klein argues that physicians should be made aware if pharmacies switch a physician-prescribed product for a biosimilar.
The Diamond Stroke Center is named after one of ANA’s founders, Dr. B. Franklin Diamond.
This bill ensures that patients and physicians are made aware if the pharmacist substitutes a biosimilar product.
Fifteen members of the American Headache Society reviewed the existing literature and developed a standard procedure for nerve blocks.
Dr. Burke is one of ANA’s longest-serving physicians.